Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) CEO Najla Guthrie joined Steve Darling from Proactive to share results from Wellbeing Digital Sciences subsidiary KGK Sciences clinical trial of GJ 191 supplement which is meant to treat osteoarthritis. Guthrie telling Proactive the positive results of a randomized, double-blind, placebo-controlled intervention demonstrated that supplementation with GJ 191 provided reductions in current knee pain at six and 12 weeks. Guthrie also said more detailed results from this study will be available upon publication.
Wellbeing Digital Sciences reveals positive results from GJ 191 supplementation clinical trial
